Up to date, there are no approved targeted therapies aimed at inhibiting c-KIT and RAS/MAPK signaling pathways, even though some efforts are being made to develop tyrosine kinase inhibitors targeting c-KIT [23] and serine/tyrosine kinase inhibitors of RAS/RAF/MAPK signaling cascade to treat refractory or relapsed TGCT cases [24]. This evidence concerns the gene KIT and testicular germ cell tumor.